Skip to main content
Clinical Trials/NCT03255746
NCT03255746
Active, not recruiting
Not Applicable

HELP-HY: Health Education and sLeep Program in HYpertension

Mayo Clinic1 site in 1 country110 target enrollmentApril 19, 2018

Overview

Phase
Not Applicable
Intervention
Sleep Enhancement
Conditions
Prehypertension
Sponsor
Mayo Clinic
Enrollment
110
Locations
1
Primary Endpoint
change in 48-hour mean arterial pressure
Status
Active, not recruiting
Last Updated
3 months ago

Overview

Brief Summary

Hypertension is the major risk factor for cardiovascular and cerebrovascular diseases worldwide. The escalating prevalence of inadequate sleep now parallels that of hypertension. Observational and experimental evidence favoring a causal relation between insufficient sleep and hypertension are particularly compelling - sleeping 6 hours or less per night is associated with a 20-32% higher probability of incident hypertension. Since sleep curtailment is largely voluntary, sleep deficiency may be corrected and the detrimental health consequences potentially reversed.

In this study the investigators aim to investigate the effects of 8 weeks of sleep enhancement/extension vs health education in prehypertensive and stage 1 hypertensive subjects who report habitual short sleep (≤6.5 hours/night).

Registry
clinicaltrials.gov
Start Date
April 19, 2018
End Date
June 1, 2026
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Virend Somers, MD, PhD

Professor of Medicine

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Age: 18 to 65 (inclusive)
  • Gender: both males and females
  • Body mass index (BMI): 18.5-34.9 kg/m2
  • Habitual sleep duration \<7 hours and voluntary prolongation of sleep when circumstances allow (as indicated by napping and/or \>45 min catch-up sleep during weekends or holidays)
  • Presence of prehypertension (office systolic BP (SBP) 120-139 mmHg and/or diastolic BP (DBP) 80-89 mmHg) , Stage 1 hypertension (office SBP 140-159 mmHg and/or DBP 90-99 mmHg ) , or currently taking antihypertensive medications
  • Either on no prescription medications (other than oral contraceptive pills, or intrauterine devices) or on stable medical regimen for at least 1 month, if taking prescription medications for chronic conditions
  • Not pregnant or breast feeding and not intending to become pregnant or breast feed
  • Not a current smoker or tobacco user
  • Ability to provide written informed consent.

Exclusion Criteria

  • Vulnerable study populations will be excluded
  • Pregnancy
  • Shift-work
  • Travel across \>2 time zones in the previous month
  • Presence of overt cardiovascular diseases, diabetes, chronic kidney disease, cancer, sleep/circadian disorders, psychiatric disorders
  • If taking prescription medications for chronic conditions, change in therapy (type, frequency and/or dosage) over the previous month
  • Sleep aids
  • Habitual sleep duration ≥7 hours
  • Excessive alcohol (\>14 drinks/week in men and \>7 drinks/week in women) and/or excessive caffeine intake (\>400 mg)
  • Currently on a diet and/or actively trying to lose weight

Arms & Interventions

Sleep Enhancement

Intervention: Sleep Enhancement

Health Education

Intervention: Health Education

Outcomes

Primary Outcomes

change in 48-hour mean arterial pressure

Time Frame: 8 weeks

changes in ambulatory measure of blood pressure

Secondary Outcomes

  • changes in endothelial function(8 weeks)
  • changes in cortisol(8 weeks)
  • changes in catecholamines(8 weeks)
  • changes in angiotensin peptides(8 weeks)
  • changes in baroreflex sensitivity(8 weeks)
  • changes in 48-hour heart rate(8 weeks)
  • changes in renin(8 weeks)
  • changes in aldosterone(8 weeks)
  • changes in insulin sensitivity(8 weeks)
  • changes in body fat(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials